One Short DMT Dose Sparks Lasting Depression Relief in Phase IIa Trial
A Phase IIa randomized trial found that a single 21.5 mg IV dose of DMT, producing a ~25-minute psychedelic experience, yielded rapid and durable antidepressant effects in adults with moderate-to-severe treatment-resistant depression—MADRS scores dropped more than placebo within one week and effects persisted up to six months for some participants; efficacy correlated with the intensity of the peak experience, and the brief session could be more cost-effective and easier to implement than longer psychedelic therapies, though larger trials are needed and use is restricted to controlled clinical settings with professional support.
